GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET ANALYSIS

Global and China Osteoporosis Drugs Market, Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates, Alderonate, Risedronate, Ibandronate, Zoledronic Acid, Others, Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor), Global and China Osteoporosis Drugs Market (By Route Of Adinistration: Oral, Injectable, Others), Global and China Osteoporosis Drugs Market (By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Global and China Osteoporosis Drugs Market: Key Developments

On April 19, 2023, Zydus Group- an India-based multinational pharmaceutical company, announced that it had received approval from the United States Food and Drug Administration (USFDA) for an osteoporosis drug (Estradiol). Estradiol is an estrogenic steroid used to various indications such as postmenopausal osteoporosis and others
On March 31, 2023, Mabwell Therapeutics, Inc.- a biotechnology company, announced that China’s National Medical Products Administration (NMPA) approved MAILISHU, a denosumab biosimilar, for the treatment of osteoporosis in postmenopausal women at high risk of fracture. MAILISHU was developed by Mabwell Therapeutics, Inc.’s subsidiary, T-Mab.
In June 2020, researchers from School of Medicine CHA University- a private university in South Korea, reported that Tauroursodeoxycholic acid (The U.S. FDA-approved hydrophilic bile acid for the treatment of chronic cholestatic liver disease) may provide a favorable effect on bones and could be used for the prevention and treatment of osteoporosis.

Global and China Osteoporosis Drugs Market: Key Trends

Rising Technological Advacements : Approval and launch of AI-based products to predict osteoporosis is expected to aid in growth of the market. For instance, in May 2020, Zebra Technologies Corp- a company that provide patient identity management, mobile health devices, and business intelligence data, received U.S. FDA 510(k) clearance for its Vertebral Compression Fractures product, which automatically identifies findings suggestive of compression fractures, which enables clinicians to place patients that are at risk of osteoporosis in treatment pathways.
Adoption of Various Growth Strategies: Major players in the market are focused on approval and launch of new products to expand their product portfolio. For instance, in May 2020, TEIJIN LIMITED- a Japan-based chemical, pharmaceutical and information technology company, partnered with Radius Health, Inc.- a global biopharmaceutical company, and submitted a New Drug Application (NDA) for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at high risk for fractures.